Effect of CYP3A5*1/*3 polymorphism on blood pressure in renal transplant recipients

Transplantation Proceedings

Volumn 44, Issue 9, 2012, Pages 2596-2598

  Torio, A ^a   Auyanet, I ^a   Montes Ares, O ^a   Guerra, R M ^a   Fernandez, E J ^a   Perez, M A ^a   Ramirez, A ^a   Checa, M D ^a  

^a CHU Insular Materno Infantil   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CYTOCHROME P450 3A5; IMMUNOSUPPRESSIVE AGENT; TACROLIMUS; CALCINEURIN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A;

ADULT; ALLELE; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CONFERENCE PAPER; DIASTOLIC BLOOD PRESSURE; DNA POLYMORPHISM; FEMALE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GRAFT RECIPIENT; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; HOMOZYGOTE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHENOTYPE; TIME; TREATMENT OUTCOME;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CALCINEURIN; CYTOCHROME P-450 CYP3A; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84869016976     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2012.09.047     Document Type: Conference Paper

References (11)

1. P. Kuehl, J. Zhang, Y. Lin Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression Nat Genet 27 2001 383
2. N. Tsuchiya, S. Satoh, H. Tada Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients Transplantation 78 2004 1182
3. D.A. Hesselink, R.H. van Schaik, M. van Agteren CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients Pharmacogenet Genomics 18 2008 339
4. J.S. Chen, L.S. Li, D.R. Cheng Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus Transplant Proc 41 2009 1557
5. M. Ferraresso, S. Turolo, L. Ghio Association between CYP3A5 polymorphisms and blood pressure in kidney transplant recipients receiving calcineurin inhibitors Clin Exp Hypertens 33 2011 359
6. J.S. Cui, J. Hopper, S. Harrap Antihypertensive treatments obscure familial contributions to blood pressure variation Hypertension 41 2003 207
7. A. Chobanian, G. Bakris, H. Black Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure Hypertension 42 2003 1206
8. B. Xi, C. Wang, L. Liu Association of the CYP3A5 polymorphism (6986G>A) with blood pressure and hypertension Hypertens Res 34 2011 1216
9. E. Coto, B. Tavira, R. Marín Functional polymorphisms in the CYP3A4, CYP3A5, and CYP21A2 genes in the risk for hypertension in pregnancy Biochem Biophys Res Commun 397 2010 576
10. R. Kreutz, H. Zurcher, S. Kain The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients Pharmacogenetics 14 2004 665
11. J.N. Roy, J. Lajoie, L.S. Zijenah CYP3A5 genetic polymorphism in different ethnic populations Drug Metab Dispos 33 2005 884